Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Gastrointestinal 2Endocrine 2CNS 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 688Lymphoma, T-Cell, Cutaneous 116Keratosis, Actinic 109Skin Neoplasms 99Carcinoma, Non-Small-Cell Lung 81Mycosis Fungoides 79Neoplasm Metastasis 78Neoplasms 75Sezary Syndrome 74Lymphoma, Non-Hodgkin 72Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Follicular 64Lymphoma, Large B-Cell, Diffuse 63Lymphoma, B-Cell, Marginal Zone 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Lymphoma, Mantle-Cell 59Uveal Melanoma 58Carcinoma, Renal Cell 58Carcinoma, Basal Cell 58Lymphoma, Large-Cell, Immunoblastic 56Hodgkin Disease 56Burkitt Lymphoma 55Lymphoma 52Lymphoma, Large-Cell, Anaplastic 50Waldenstrom Macroglobulinemia 44Multiple Myeloma 44Lymphoma, Extranodal NK-T-Cell 44Breast Neoplasms 44Immunoblastic Lymphadenopathy 43Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 41

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Chordoma × Dermatologic × Clear all
NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sarcoma Oncology Research Center, LLC

Phase 1/2 Completed
34 enrolled 14 charts
DermatologicGastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chordoma, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Sarcoma, Ewing, Colorectal Neoplasms, Desmoid Tumors, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡